Acuta Capital Partners, LLC Editas Medicine, Inc. Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 50,000 shares of EDIT stock, worth $62,500. This represents 0.32% of its overall portfolio holdings.
Number of Shares
50,000Holding current value
$62,500% of portfolio
0.32%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding EDIT
# of Institutions
228Shares Held
54.2MCall Options Held
412KPut Options Held
355K-
Black Rock Inc. New York, NY7.78MShares$9.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$8.53 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$3.43 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$2.7 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$2.34 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $85.9M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...